University of California

Other

Syntex (u.s.a.) Inc.

Arch Development Corporation

Henry Ford Health System

Galileo Laboratories, Inc.

Phillip Crews

Randall S Alberte

Thomas R Matthews

Richard C Zimmerman

James S Todd

Frederick A Valeriote

Theodore Holman

Guy Miller

Sheng Lin

Lesley A Brown

Nicholas Lorig-Roach

Jennifer Carroll

Karen Tenney

Steve Bobzin

Wayne D Inman

Erin P McCauley

Paul Horton

Provided are pyrroloquinolin compounds of formula (1) or (II). In certain aspects, the pyrroloquinolin compounds are therapeutic, e.g., for treating a cell proliferative disorder. Also provided are conjugates that include the pyrroloquinolin compounds of the present disclosure. Compositions, e.g., pharmaceutical compositions, that include the pyrroloquinolin compounds and conjugates of the present disclosure are also provided. Further provided are therapeutic methods involving the administration of the pyrroloquinolin compounds, conjugates or compositions of the present disclosure. Kits that include the pyrroloquinolin compounds, conjugates or compositions are also provided. 

Pyrroloquinolin compounds and methods of using same

Compounds that are effective lipoxygenase inhibitors, and methods and pharmaceutical compositions for inhibiting lipoxygenases and for treatment of lipoxygenase-mediated conditions in humans and other subjects. The compounds, methods and pharmaceutical compositions utilize subersic terpenoids, jaspic terpenoids, igernellic terpenoids, hippospongic terpenoids, halicondric terpenoids, dictyodendric terpenoids, and/or heteronemic terpenoids, and synthetic derivatives or analogs thereof. Exemplary compounds include (&minus;)-subersic acid, (&plus;)-subersin, jaspaquinol, (&minus;)-jaspic acid, igernellin, halisufate 7, and hipposulfate C and D, and derivatives thereof.

Sponge-derived terpenoids and methods of use

p-Sulfoxy cinnamic acid isolated from methanolic extracts of the eelgrass Zostera marina having significant antifouling aquatic properties. p-Sulfoxy cinnamic acid was synthesized in the laboratory from p-coumaric acid, and antifouling activity was identical to the natural compound in laboratory bioassays. In addition, sulfate esters of other phenolic acids showed similar antifouling activity, suggesting that the sulfate ester was responsible for the antifouling effect.

Phenolic acid sulfate esters for prevention of marine biofouling

p-sulfoxy cinnamic acid isolated from methanolic extracts of the eelgrass Zostera marina having significant antifouling aquatic properties. p-sulfoxy cinnamic acid was synthesized in the laboratory from p-coumaric acid, and antifouling activity was identical to the natural compound in laboratory bioassays. In addition, sulfate esters of other phenolic acids showed similar antifouling activity, suggesting that the sulfate ester was responsible for the antifouling effect.

This invention is directed to novel compounds of Formula (I): ##STR1## wherein R is hydrogen or methyl, or a pharmaceutically acceptable salt thereof and pharmaceutical compositions formulated therewith. This invention is also directed to a method for treating helminthiasis and for inhibiting reverse transcriptase activity in an animal by the administration of compounds of Formula (I).

Alkaloids of marine origin

This invention is directed to a method for treating helminthiasis which comprises administering to an animal in need thereof an anthelmintically effective amount of a compound of Formula (I): ##STR1## where R.sup.1 is hydrogen or --SR.sup.2,

Anthelmintic dysinins of marine origin

Growing community of inventors

Santa Cruz, CA, United States of America

Phillip Crews